 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 February 1994 | Volume 120 Issue 4 | Pages 278-286
Objective: To evaluate the safety and efficacy of all-trans retinoic acid to induce complete remission and to examine its effects on duration of remission and survival in patients with acute promyelocytic leukemia.
Design: Phase II evaluation and comparison with historical control patients.
Setting: Tertiary care cancer referral center.
Patients: Consecutive patients with morphologic diagnoses of acute promyelocytic leukemia were treated during a 2-year period with all-trans retinoic acid (daily oral dose, 45 mg/m2). Newly diagnosed patients discontinued the drug approximately 30 days after they achieved complete remission, at which time they received three courses of combination chemotherapy. Patients treated with previous cytotoxic chemotherapy who then relapsed were continued on all-trans retinoic acid as "maintenance" therapy until they relapsed again.
Results: 56 patients entered the study: 34 were newly diagnosed and 22 had relapsed from previous treatment. Fifty-one patients subsequently were found to have the PML/RAR-
Conclusions: All-trans retinoic acid is an effective agent to induce remission in patients with a molecular diagnosis of acute promyelocytic leukemia, but remissions are short and resistance develops rapidly. Although the incidence of early death was not reduced, the use of all-trans retinoic acid to induce remission, followed by cytotoxic chemotherapy for "consolidation," was associated with longer survival times when compared with historical controls treated only with chemotherapy. Additional studies to prevent or mitigate consequences of the "retinoic acid syndrome" and to identify specific patients who might benefit from earlier intervention with chemotherapy are needed to maximize the advantages of this approach.
Author and Article Information
From the Memorial Sloan-Kettering Cancer Center and the Cornell University Medical College, New York, New York.
ARTICLE
All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study
gene rearrangement indicative of acute promyelocytic leukemia, and 44 of these patients achieved complete remission (86%; 95% CI, 76% to 96%). A distinctive respiratory distress syndrome developed in 13 patients (23%) during treatment, and 5 patients (9%; CI, 3% to 20%) died of this complication. The 5 patients who lacked PML/RAR- rearrangements were withdrawn and given chemotherapy. The 13 patients given all-trans retinoic acid alone as maintenance therapy (10 of whom had relapsed from a chemotherapy-induced remission) had a median duration of remission of only 3.5 months (range, 1 to 23 months). Only 3 of 19 patients who relapsed from a remission induced by all-trans retinoic acid could be brought into remission again using this drug. The median survival time of all newly diagnosed patients has not been reached, but it now exceeds 31 months (range, 0.4 to 36+ months). No decrease in the early mortality rate was observed compared with a historical control group composed of 80 consecutive, newly diagnosed patients treated only with chemotherapy at this center; however, overall survival was superior.
Requests for Reprints: Raymond P. Warrell, Jr., MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
Grant Support: In part by FD-R-000764 from the Orphan Products Division, Food and Drug Administration; by CA-57645 and CA-55449 from the National Cancer Institute; by EDT-47 and PT-381 from the American Cancer Society; and by the Lymphoma Foundation.
Acknowledgments: The authors thank Teresa Snyder, RN, Marianne Campbell, RN, and Helen Wrobleski, RN, for clinical support; Susan McKenzie and Angelita Naval for technical assistance; and our colleagues in the Leukemia Service for their expertise in clinical management.
This article has been cited by other articles:
|
|
 |
|
  J. de la Serna, P. Montesinos, E. Vellenga, C. Rayon, R. Parody, A. Leon, J. Esteve, J. M. Bergua, G. Milone, G. Deben, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin Blood, April 1, 2008; 111(7): 3395 - 3402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Braiteh and R. Kurzrock Uncommon tumors and exceptional therapies: paradox or paradigm? Mol. Cancer Ther., April 1, 2007; 6(4): 1175 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al. Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group J. Clin. Oncol., December 20, 2006; 24(36): 5703 - 5710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Mathews, B. George, K. M. Lakshmi, A. Viswabandya, A. Bajel, P. Balasubramanian, R. V. Shaji, V. M. Srivastava, A. Srivastava, and M. Chandy Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity Blood, April 1, 2006; 107(7): 2627 - 2632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Sanz, M. S. Tallman, and F. Lo-Coco Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia Oncologist, November 1, 2005; 10(10): 806 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Ortega, L. Madero, G. Martin, A. Verdeguer, P. Garcia, R. Parody, J. Fuster, A. Molines, A. Novo, G. Deben, et al. Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group J. Clin. Oncol., October 20, 2005; 23(30): 7632 - 7640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Sanz, M. S. Tallman, and F. Lo-Coco Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia Blood, April 15, 2005; 105(8): 3019 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Battistella, L. D Burry, and J. T Seki Retinoic acid syndrome after one dose of all-transretinoic acid Journal of Oncology Pharmacy Practice, September 1, 2004; 10(3): 149 - 154. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Sanz, G. Martin, M. Gonzalez, A. Leon, C. Rayon, C. Rivas, D. Colomer, E. Amutio, F. J. Capote, G. A. Milone, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group Blood, February 15, 2004; 103(4): 1237 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Haugen, L. L. Larson, U. Pugazhenthi, W. R. Hays, J. P. Klopper, C. A. Kramer, and V. Sharma Retinoic Acid and Retinoid X Receptors Are Differentially Expressed in Thyroid Cancer and Thyroid Carcinoma Cell Lines and Predict Response to Treatment with Retinoids J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 272 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Barbey, J. C. Pezzullo, and S. L. Soignet Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies J. Clin. Oncol., October 1, 2003; 21(19): 3609 - 3615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Colucciello Pseudotumor Cerebri Induced by All-trans Retinoic Acid Treatment of Acute Promyelocytic Leukemia Arch Ophthalmol, July 1, 2003; 121(7): 1064 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide Oncologist, April 1, 2002; 7(90001): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-C. Zhou, S. H. Kim, W. Ding, C. Schultz, R. P. Warrell Jr, and R. E. Gallagher Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo Blood, February 15, 2002; 99(4): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Jung, J. E. Choi, S. T. Hahn, C. K. Min, C. C. Kim, and S. H. Park Radiologic Features of All-Trans-Retinoic Acid Syndrome Am. J. Roentgenol., February 1, 2002; 178(2): 475 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe Acute promyelocytic leukemia: evolving therapeutic strategies Blood, February 1, 2002; 99(3): 759 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. U. Kurz, S. E. Wilson, K. B. Leader, B. P. Sampey, W. P. Allan, J. C. Yalowich, and D. J. Kroll The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase II{alpha} Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines Mol. Cancer Ther., December 1, 2001; 1(2): 121 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Jurcic, S. D. Nimer, D. A. Scheinberg, T. DeBlasio, R. P. Warrell Jr, and W. H. Miller Jr Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia Blood, November 1, 2001; 98(9): 2651 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Soignet Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia Oncologist, April 1, 2001; 6(90002): 11 - 16. [Abstract] [Full Text]
|
|
|
|
|
|
D. Douer, E. Estey, S. Santillana, J. M. Bennett, G. Lopez-Bernstein, K. Boehm, and T. Williams Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid Blood, January 1, 2001; 97(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Gladwin, X. L. Yao, M. Cowan, X. L. Huang, R. Schneider, L. R. Grant, C. Logun, and J. H. Shelhamer Retinoic acid reduces p11 protein levels in bronchial epithelial cells by a posttranslational mechanism Am J Physiol Lung Cell Mol Physiol, December 1, 2000; 279(6): L1103 - L1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shao, A. Rosenauer, K. Mann, C.-P. B. Chang, C. Rachez, L. P. Freedman, and W. H. Miller Jr Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells Blood, September 15, 2000; 96(6): 2233 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Camacho, S. L. Soignet, S. Chanel, R. Ho, G. Heller, D. A. Scheinberg, R. Ellison, and R. P. Warrell Jr Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide J. Clin. Oncol., July 1, 2000; 18(13): 2620 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Jurcic, T. DeBlasio, L. Dumont, T.-J. Yao, and D. A. Scheinberg Molecular Remission Induction with Retinoic Acid and Anti-CD33 Monoclonal Antibody HuM195 in Acute Promyelocytic Leukemia Clin. Cancer Res., February 1, 2000; 6(2): 372 - 380. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Sanz, G. Martin, C. Rayon, J. Esteve, M. Gonzalez, J. Diaz-Mediavilla, P. Bolufer, E. Barragan, M. J. Terol, J. D. Gonzalez, et al. A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RARalpha -Positive Acute Promyelocytic Leukemia Blood, November 1, 1999; 94(9): 3015 - 3021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Burnett, D. Grimwade, E. Solomon, K. Wheatley, and A. H. Goldstone Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial Blood, June 15, 1999; 93(12): 4131 - 4143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Menell, G. M. Cesarman, A. T. Jacovina, M. A. McLaughlin, E. A. Lev, and K. A. Hajjar Annexin II and Bleeding in Acute Promyelocytic Leukemia N. Engl. J. Med., April 1, 1999; 340(13): 994 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome? J. Clin. Oncol., January 1, 1999; 17(1): 293 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. NICOLLS, L. S. TERADA, R. M. TUDER, S. A. PRINDIVILLE, and M. I. SCHWARZ Diffuse Alveolar Hemorrhage with Underlying Pulmonary Capillaritis in the Retinoic Acid Syndrome Am. J. Respir. Crit. Care Med., October 1, 1998; 158(4): 1302 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ding, Y.-P. Li, L. M. Nobile, G. Grills, I. Carrera, E. Paietta, M. S. Tallman, P. H. Wiernik, and R. E. Gallagher Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RARalpha Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy Blood, August 15, 1998; 92(4): 1172 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Barbui, G. Finazzi, and A. Falanga The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia Blood, May 1, 1998; 91(9): 3093 - 3102. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Sanz, G. Martin, J. Diaz-Mediavilla, M. S. Tallman, F. R. Appelbaum, and C. A. Schiffer All-trans-Retinoic Acid in Acute Promyelocytic Leukemia N. Engl. J. Med., February 5, 1998; 338(6): 393 - 394. [Full Text]
|
|
|
|
|
|
M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, A. Ogden, L. Shepherd, C. Willman, C. D. Bloomfield, J. M. Rowe, et al. All-trans-Retinoic Acid in Acute Promyelocytic Leukemia N. Engl. J. Med., October 9, 1997; 337(15): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Larson, D. C. Brown, and L. A. Sklar Retinoic Acid Induces Aggregation of the Acute Promyelocytic Leukemia Cell Line NB-4 by Utilization of LFA-1 and ICAM-2 Blood, October 1, 1997; 90(7): 2747 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Gallagher, C. L. Willman, J. L. Slack, J. W. Andersen, Y.-P. Li, D. Viswanatha, C. D. Bloomfield, F. R. Appelbaum, C. A. Schiffer, M. S. Tallman, et al. Association of PML-RARalpha Fusion mRNA Type With Pretreatment Hematologic Characteristics But Not Treatment Outcome in Acute Promyelocytic Leukemia: An Intergroup Molecular Study Blood, August 15, 1997; 90(4): 1656 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mandelli, D. Diverio, G. Avvisati, A. Luciano, T. Barbui, C. Bernasconi, G. Broccia, R. Cerri, M. Falda, G. Fioritoni, et al. Molecular Remission in PML/RARalpha -Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy Blood, August 1, 1997; 90(3): 1014 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Banker, M. Groudine, T. Norwood, and F. R. Appelbaum Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia Blood, January 1, 1997; 89(1): 243 - 255. [Abstract] [Full Text] [PDF]
|
|
Article
